ScholarX: KIM, JI YEON

Detailed Information

KIM, JI YEON (김지연)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

3:10||Metastatic breast cancer:8||breast cancer:6||Neoadjuvant chemotherapy:5||5:4||1:3||Pathologic complete response:3||neoadjuvant chemotherapy:3||2:3||chemotherapy:3||6:3||Obesity:3||Breast cancer:3||236:2||Circulating tumor cells:2||PraderWilli syndrome:2||81:2||Triplenegative breast cancer:2||Advanced breast cancer:2||26156632482667:2||Young breast cancer:2||4:2||Prognostic biomarkers:2||295:2||Docetaxel:2||cMET:2||12:2||Hyperphagia:2||92:2||triplenegative breast cancer:2||residual cancer burden:2||Breast Neoplasms:2||Radiation therapy:2||immunotherapy:2||metastatic breast cancer:2||2614923532237076502700:2||Cellfree DNA:2||Chemotherapy:2||HER2positive breast cancer:2||Eribulin:1||Ethanol:1||Exosomes:1||Extracellular vesicles:1||Gene expression profiling:1||Genes:1||Genetic:1||Genomic profile:1||HER2 negative:1||HER2:1||HER2 positive:1||HER2+breast cancer:1||Heart failure:1||Hepatolenticular degeneration:1||Homologous recombination repair deficiengy (HRD):1||Hormone receptor positive:1||Huaiyangshan banyangvirus:1||Hypertriglyceridemia:1||Immune checkpoint inhibitors:1||Immunerelated adverse events:1||Influenza:1||Ki67:1||LAG3:1||Leptomeningeal metastasis:1||Luminal breast cancer:1||Lymphatic irradiations:1||Machine learning:1||Magnetic resonance imaging (MRI):1||MitoRAISE:1||Mitochondrial function:1||Molecular subtype:1||Mutation:1||NEUROD1:1||Neoadjuvant:1||Neoadjuvant TCHP regimen:1||Neoplasm metastasis:1||Neoplasms, Multiple Primary:1||Nerve growth factor:1||Neuroendocrine tumor:1||Nivolumab:1||Nonalcoholic fatty liver disease:1||Obstructive sleep apnea:1||Oncology:1||Overall survival:1||PD1:1||PDL1:1||POU2F3:1||Palbociclib:1||Palliative:1||Patient reported outcome:1||Pembrolizumab:1||Performance:1||Pertuzumab:1||PowerChek:1||PowerChek SFTSV Realtime PCR kit:1||Premenopausal:1||Primary systemic therapy:1||Prognosis:1||Prognostic biomarker:1||Progressionfree survival:1||Prospective cohort study:1||Pulmonary heart disease:1||Questionnaire:1||RSV:1||Real world evidence:1||RealWorld Data:1||Realtime PCR:1||Recurrence:1||Relative mitochondrial ATP synthesis rate:1||Retrospective Analysis:1||SARSCoV2:1||SFTS virus:1||SFTSQS kit:1||Small cell lung cancer:1||Social support:1||Stomach neoplasms:1||Survival:1||Survival Outcome:1||TP53 mutation:1||Trastuzumab:1||Treatment outcome:1||Triple negative breast neoplasms:1||Turnaround time:1||VP shunt:1||adjuvant cohort:1||biomarkers:1||breast neoplasm:1||computational biology:1||disease free survival:1||endocrine symptoms:1||endocrine therapy:1||exosomes:1||extracellular vesicles:1||first line:1||gemcitabine:1||gene expression:1||genetic polymorphism:1||hormone receptor:1||hormone receptor positive:1||hormone receptor positive (HR+):1||immune checkpoint inhibitor:1||isolated locoregional recurrence:1||machine learning:1||metastatic breast cancer (MBC):1||metastatic cancer:1||molecular subtype:1||mtDNA copy number:1||palbociclib with letrozole:1||pathologic complete response:1||patientreported outcome:1||pertuzumab:1||pharmacogenetics:1||prediction model:1||pregnancy:1||premenopausal:1||primary resistance:1||progesterone receptor:1||prognosis:1||prognostic biomarker:1||prospective cohort:1||real time prediction:1||recurrence:1||recurrence model:1||residual proliferative cancer burden:1||second line treatment:1||surveillance:1||survival:1||triple negative breast cancer:1||tumor:1||vascular endothelial growth factor A:1||1579:1||228:1||2613278:1||26143675592760:1||2614922769:1||2614923532237076505110:1||26149235322373:1||26149256512790:1||26156632482733:1||2813189490:1||283217:1||2832172472:1||312:1||3282330646143760:1||328246447627374510025:1||65:1||8:1||A proliferationinducing ligand:1||ASCL1:1||ATP:1||Acute pancreatitis:1||Adjuvant Treatment:1||AntiHER2 targeted therapy:1||Appetite:1||Axilla:1||Breast cancer subtype:1||Breast carcinoma:1||Breast neoplasm:1||Breast neoplasms:1||CXC motif chemokine ligand 13:1||CDK4/6 inhibitor:1||CDW:1||COVID19:1||Clinical trial:1||Cohort profile:1||Diabetic ketoacidosis:1||Drug resistance:1||Eating disorder:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE